Australia is anticipating the arrival of Retatrutide, a novel medication developed by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates remarkable results in testing, indicating https://getsocialsource.com/story7469380/novo-nordisk-s-retatrutide-australia-a-new-hope-for-weight-management